Clopidogrel Tablet
Product Images NDC 70518-4373

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 70518-4373). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This text contains information about Clopidogrel tablets with a dosage of 75 mg and a quantity of 90 tablets. It provides details such as the NDC number, manufacturer (Ascend Labs, LLC), storage instructions, and dosage recommendation. The medication is repackaged by RemedyRepack Inc. and is intended for prescription-only use.*

FDA Label Image

Clop02-a (Clop02 A)

FDA Label Image

Clop03-a (Clop03 A)

This text provides data on the cumulative event rate for cardiovascular death, myocardial infarction, and stroke for patients taking placebo with aspirin versus clopidogrel with aspirin over a specific follow-up period. The data suggests a statistically significant difference between the two groups, with a p-value of 0.00009. The study also mentions the use of other standard therapies during the trial.*

FDA Label Image

Clop04-a (Clop04 A)

This text appears to contain information regarding the administration of medications such as Heparin/LMWH, Aspirin, GPIIb/la Antag, Beta-Blocker, and Ace Inhibitor, as well as the previous medical history of patients including MI and stroke. Additionally, it provides statistical data on the usage of Clopidogrel and Placebo in different groups. These details could be part of a research study or clinical trial evaluating the effectiveness of these medications in patients with a history of cardiovascular events.*

FDA Label Image

Clop08-a (Clop08 A)

This text provides information on the cumulative event rates for fatal or non-fatal vascular events over time for patients treated with aspirin and clopidogrel. The data shows the event rates at different time points (6, 12, 18, 24, and 30 months) of follow-up. The P-value of 0.045 indicates a statistically significant difference between the two treatments.*

FDA Label Image

Clop_01 (Clop 01)

FDA Label Image

Clop_05 (Clop 05)

The text provided describes the comparison of mortality rates between a placebo group and a group receiving Clopidogrel tablets. The data shows 1845 deaths (8.1%) in the placebo group and 1726 deaths (7.5%) in the group receiving Clopidogrel tablets. There is a 7% proportional risk reduction associated with Clopidogrel tablets with a p-value of 0.03. The study was conducted over 28 days with all treated patients also receiving aspirin.*

FDA Label Image

Clop_06 (Clop 06)

This description provides data on the comparison between a placebo and Clopidrogel Tablets in reducing the risk of death, reinfarction, or stroke before discharge. The study reveals a 9% proportional risk reduction with Clopidrogel Tablets compared to the placebo group, with statistical significance (p=0.002). The graph displays the progression of events over 28 days since randomization, with all treated patients also receiving aspirin.*

FDA Label Image

Clop_07 (Clop 07)

This is a statistical data table showing detailed information about a subgroup analysis related to gender, age, hours since onset, vital signs like systolic blood pressure and heart rate, use of fibrinolytic agents, and treatment with Clopidogrel tablets and Placebo in a study. The table presents the number of cases in different categories and corresponding percentages, allowing for comparisons and analyses.*

FDA Label Image

Clop_09 (Clop 09)

The provided text includes data on the number and percentage of patients taking Clopidogrel tablets and Aspirin in relation to stroke and PAD conditions. It also mentions hazard ratios with corresponding confidence intervals. The information seems to be part of a study or report evaluating the efficacy of these medications in specific conditions.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.